Which ICD‑10 code should be used when ordering a p‑tau217 test to evaluate for Alzheimer’s disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10 Coding for P-Tau217 Testing in Alzheimer's Disease Evaluation

When ordering p-tau217 testing to evaluate for Alzheimer's disease, use the ICD-10 code that reflects the patient's current clinical presentation: G31.84 (Mild cognitive impairment) for MCI, G30.9 (Alzheimer's disease, unspecified) for suspected AD dementia, or R41.81 (Age-related cognitive decline) for subjective cognitive concerns with objective impairment.

Clinical Context for Appropriate Testing

Before ordering p-tau217, the patient must meet specific clinical criteria 1:

  • Objective cognitive impairment documented on formal testing (not just subjective complaints)
  • Clinical suspicion of AD based on comprehensive assessment
  • Appropriate neuroimaging completed to rule out structural causes
  • Collateral history supporting cognitive decline

Do not order p-tau217 for:

  • Asymptomatic individuals (research only) 1
  • Patients with subjective cognitive decline but normal objective testing 1
  • Cases where non-neurodegenerative causes (anxiety, depression) are primary 1
  • Rapidly progressive dementia where Creutzfeldt-Jakob disease is suspected (p-tau217 can be falsely elevated) 1

Specific ICD-10 Code Selection

For Mild Cognitive Impairment (MCI)

Use G31.84 when the patient has:

  • Cognitive concern with objective impairment on testing
  • Preserved independence in functional abilities
  • Does not meet dementia criteria
  • Clinical features suggesting possible AD etiology 2

For Suspected AD Dementia

Use G30.9 (or more specific G30.0 for early-onset, G30.1 for late-onset) when:

  • Patient meets dementia criteria with significant functional impairment
  • Clinical presentation consistent with AD
  • Testing ordered to confirm AD pathology 2

For Subjective Cognitive Decline with Objective Findings

Use R41.81 when:

  • Patient reports cognitive concerns
  • Objective testing shows mild impairment below expected for age/education
  • Does not yet meet MCI criteria but warrants biomarker evaluation 1

Important Caveats

P-tau217 is the preferred blood biomarker with superior diagnostic accuracy compared to p-tau181, p-tau231, or plasma Aβ42/Aβ40 ratio 1. However, results require careful interpretation:

  • Two cut-point approach is mandatory: Results fall into low, indeterminate, or high ranges 1
  • Approximately 20% of results will be indeterminate and require CSF or PET confirmation 1
  • Confounding factors include renal failure (elevated eGFR affects levels), body mass index, and peripheral neuropathies 3, 4
  • A high result must be interpreted with age and clinical context, as AD pathology increases with age even in cognitively normal individuals 1

Sample Handling Requirements

Ensure your laboratory follows proper protocols 1, 5:

  • Non-adsorbent collection tubes
  • Appropriate separation, cooling, and cold chain maintenance
  • Testing in UKAS-accredited or equivalent clinical laboratory
  • CE/CA marked assays (Lumipulse, ALZpath platforms validated) 5, 6

The ICD-10 code should reflect the clinical syndrome being evaluated, not the test being ordered. The p-tau217 test serves as an adjunct to comprehensive clinical assessment, never as a standalone diagnostic tool 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.